Evidence map›Paper›PMID 39264853›Full record

ArticleJCI insight2024

Targeted long-read sequencing enriches disease-relevant genomic regions of interest to provide complete Mendelian disease diagnostics.

Kenji Nakamichi, Jennifer Huey, Riccardo Sangermano, Emily M Place, Kinga M Bujakowska, Molly Marra, Lesley A Everett, Paul Yang, Jennifer R Chao, Russell N Van Gelder and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Genomics in Health and Biomedicine.Advances in experimental medicine and biology · 2026
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenji NakamichiDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Jennifer HueyDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Riccardo SangermanoOcular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Emily M PlaceOcular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Kinga M BujakowskaOcular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Molly MarraCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
Lesley A EverettCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
Paul YangCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
Jennifer R ChaoDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Russell N Van GelderDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.
Debarshi MustafiDepartment of Ophthalmology, University of Washington, Seattle, Washington, USA.

Funding

Vision Research CoreP30EY001730 · NEI · UNIVERSITY OF WASHINGTON · PI Jay Neitz · 1985 to 2026
$23.5M
P30 Core Grant for Vision ResearchP30EY014104 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Janey L Wiggs · 2002 to 2026
$15.1M
University of Washington (UW) Mendelian Genomics Data Coordinating CenterU24HG011746 · NHGRI · UNIVERSITY OF WASHINGTON · PI Susanne May, ALI SHOJAIE · 2021 to 2026
$14.8M
Metabolic dysfunction from ECM remodeling in diseases of human RPER01EY034364 · NEI · UNIVERSITY OF WASHINGTON · PI Jennifer Rayming Chao, Jianhai Du · 2022 to 2026
$2.8M
The role of non-coding variants in Usher diseaseK08EY033789 · NEI · UNIVERSITY OF WASHINGTON · PI Debarshi Mustafi · 2023 to 2026
$921k
Molecular determinants of pathogenicity in viral conjunctivitisR21EY033174 · NEI · UNIVERSITY OF WASHINGTON · PI VAN GELDER, RUSSELL N. · 2021 to 2022
$477k
NEI NIH HHS K08 EY033789NEI NIH HHS P30 EY001730NEI NIH HHS P30 EY014104NEI NIH HHS R01 EY034364NEI NIH HHS R21 EY033174NHGRI NIH HHS U24 HG011746
6 · The paper itself

Abstract

Despite advances in sequencing technologies, a molecular diagnosis remains elusive in many patients with Mendelian disease. Current short-read clinical sequencing approaches cannot provide chromosomal phase information or epigenetic information without further sample processing, which is not routinely done and can result in an incomplete molecular diagnosis in patients. The ability to provide phased genetic and epigenetic information from a single sequencing run would improve the diagnostic rate of Mendelian conditions. Here, we describe targeted long-read sequencing of Mendelian disease genes (TaLon-SeqMD) using a real-time adaptive sequencing approach. Optimization of bioinformatic targeting enabled selective enrichment of multiple disease-causing regions of the human genome. Haplotype-resolved variant calling and simultaneous resolution of epigenetic base modification could be achieved in a single sequencing run. The TaLon-SeqMD approach was validated in a cohort of 18 individuals with previous genetic testing targeting 373 inherited retinal disease (IRD) genes, yielding the complete molecular diagnosis in each case. This approach was then applied in 2 IRD cases with inconclusive testing, which uncovered noncoding and structural variants that were difficult to characterize by standard short-read sequencing. Overall, these results demonstrate TaLon-SeqMD as an approach to provide rapid phased-variant calling to provide the molecular basis of Mendelian diseases.

Indexed as

High-Throughput Nucleotide SequencingComputational BiologyFemaleGenetic Diseases, InbornGenetic TestingGenome, HumanGenomicsHaplotypesHumansMaleRetinal DiseasesSequence Analysis, DNAGenetic diseasesGeneticsMolecular geneticsOphthalmologyRetinopathy

Identifiers

PMID39264853
PMCPMC11530123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.